Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC.

ABSTRACT:

Introduction

Subgroup analyses from clinical studies have suggested that among patients with metastatic NSCLC receiving chemotherapy, females may derive less benefit from the addition of the vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab (BV) than males. This has raised the question of whether estrogen may affect the response to antiangiogenic therapy.

Methods

To address this, we investigated the effects of estrogen on tumor growth, angiogenesis, and the response to BV in human xenograft models of NSCLC.

Results

We observed that estrogen induced marked resistance to BV, which was accompanied by a 2.3-fold increase in tumor vascular pericyte coverage (p = 0.01) and an up-regulation of proangiogenic factors, VEGF and platelet-derived growth fa

SUBMITTER: Patel SA 

PROVIDER: S-EPMC10324274 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature